UY37507A - Moduladores de ror gamma (ror¿) - Google Patents

Moduladores de ror gamma (ror¿)

Info

Publication number
UY37507A
UY37507A UY0001037507A UY37507A UY37507A UY 37507 A UY37507 A UY 37507A UY 0001037507 A UY0001037507 A UY 0001037507A UY 37507 A UY37507 A UY 37507A UY 37507 A UY37507 A UY 37507A
Authority
UY
Uruguay
Prior art keywords
ror
gamma modulators
formula
compounds
modulators
Prior art date
Application number
UY0001037507A
Other languages
English (en)
Inventor
Maria Gerardus Barbara Cals Joseph
David Machnik
Bernardus Nabuurs Sander
Sabuco Jean-François
Original Assignee
Lead Pharma Holding Bv
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv, Sanofi Sa filed Critical Lead Pharma Holding Bv
Publication of UY37507A publication Critical patent/UY37507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a los compuestos de acuerdo con la (Fórmula IA) o (Fórmula IB):o una sal farmacéuticamente aceptable de los mismos Los compuestos se pueden utilizar como inhibidores de ROR¿ y son útiles para el tratamiento de las enfermedades mediadas por ROR¿.
UY0001037507A 2016-12-05 2017-12-01 Moduladores de ror gamma (ror¿) UY37507A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16202175 2016-12-05

Publications (1)

Publication Number Publication Date
UY37507A true UY37507A (es) 2018-06-29

Family

ID=57482312

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037507A UY37507A (es) 2016-12-05 2017-12-01 Moduladores de ror gamma (ror¿)

Country Status (34)

Country Link
US (3) US10196350B2 (es)
EP (1) EP3548016B1 (es)
JP (1) JP6955563B2 (es)
KR (1) KR102554776B1 (es)
CN (1) CN110352054B (es)
AR (1) AR110481A1 (es)
AU (1) AU2017373593B2 (es)
BR (1) BR112019010461A2 (es)
CA (1) CA3045946A1 (es)
CL (1) CL2019001406A1 (es)
CO (1) CO2019007186A2 (es)
CR (1) CR20190321A (es)
DK (1) DK3548016T3 (es)
DO (1) DOP2019000119A (es)
EA (1) EA201991373A1 (es)
EC (1) ECSP19047767A (es)
ES (1) ES2830759T3 (es)
HU (1) HUE052470T2 (es)
IL (1) IL267045B (es)
LT (1) LT3548016T (es)
MA (1) MA46965B1 (es)
MX (1) MX2019006517A (es)
MY (1) MY194174A (es)
NZ (1) NZ755105A (es)
PE (1) PE20191545A1 (es)
PH (1) PH12019501231A1 (es)
PL (1) PL3548016T3 (es)
PT (1) PT3548016T (es)
RS (1) RS60964B1 (es)
TW (1) TWI705958B (es)
UA (1) UA123751C2 (es)
UY (1) UY37507A (es)
WO (1) WO2018104288A1 (es)
ZA (1) ZA201902288B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
US10196350B2 (en) 2016-12-05 2019-02-05 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007486A2 (en) 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
CA2872014A1 (en) 2012-05-08 2013-11-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
JP6461960B2 (ja) 2013-12-05 2019-01-30 リード ファーマ ホールディング ビー．ブイ． ＲＯＲガンマ（γ）モジュレータ
TW201605797A (zh) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 作為ror伽馬調節物的雙環雜芳基化合物
AU2014365915C1 (en) 2013-12-19 2019-04-04 Merck Patent Gmbh Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
EP3527569B1 (en) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
EP3122721A4 (en) * 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
DK3131902T3 (da) 2014-04-14 2019-09-02 Boehringer Ingelheim Int Forbindelser som ROR-gamma-modulatorer
LT3294713T (lt) 2015-05-15 2021-06-10 Aurigene Discovery Technologies Limited Pakeisti tetrahidrokvinoliniai junginiai, kaip ror gama moduliatoriai
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
PL3331863T3 (pl) 2015-08-03 2020-08-10 Glenmark Pharmaceuticals S.A. Nowe związki jako modulatory ror gamma
WO2017213137A1 (ja) 2016-06-09 2017-12-14 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用薬剤
US10196350B2 (en) 2016-12-05 2019-02-05 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
JP2019026575A (ja) 2017-07-27 2019-02-21 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用殺菌剤

Also Published As

Publication number Publication date
EP3548016A1 (en) 2019-10-09
CA3045946A1 (en) 2018-06-14
KR20190096365A (ko) 2019-08-19
PH12019501231A1 (en) 2019-09-23
AU2017373593B2 (en) 2022-04-07
ES2830759T3 (es) 2021-06-04
JP6955563B2 (ja) 2021-10-27
PT3548016T (pt) 2020-10-08
WO2018104288A1 (en) 2018-06-14
EP3548016B1 (en) 2020-09-02
JP2020500886A (ja) 2020-01-16
CO2019007186A2 (es) 2019-08-20
IL267045A (en) 2019-07-31
US11299456B2 (en) 2022-04-12
CN110352054B (zh) 2022-11-01
RS60964B1 (sr) 2020-11-30
AU2017373593A1 (en) 2019-07-25
HUE052470T2 (hu) 2022-02-28
UA123751C2 (uk) 2021-05-26
US10196350B2 (en) 2019-02-05
KR102554776B1 (ko) 2023-07-11
MX2019006517A (es) 2019-08-22
ECSP19047767A (es) 2019-08-30
TW201835038A (zh) 2018-10-01
CN110352054A (zh) 2019-10-18
PE20191545A1 (es) 2019-10-24
CL2019001406A1 (es) 2019-10-18
NZ755105A (en) 2023-01-27
MA46965B1 (fr) 2020-12-31
DK3548016T3 (da) 2020-11-16
EA201991373A1 (ru) 2019-11-29
AR110481A1 (es) 2019-04-03
US20200190028A1 (en) 2020-06-18
US20190119204A1 (en) 2019-04-25
US20180162808A1 (en) 2018-06-14
BR112019010461A2 (pt) 2019-09-10
MY194174A (en) 2022-11-17
IL267045B (en) 2021-07-29
TWI705958B (zh) 2020-10-01
PL3548016T3 (pl) 2021-02-08
ZA201902288B (en) 2020-10-28
DOP2019000119A (es) 2019-09-30
CR20190321A (es) 2019-09-11
LT3548016T (lt) 2021-01-11

Similar Documents

Publication Publication Date Title
UY36708A (es) MODULADORES DE ROR GAMMA (RORy)
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2018002060A2 (es) Compuestos farmacéuticos
UY36748A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
UY37098A (es) Moduladores de ror-gamma
SV2016005192A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36709A (es) Moduladores de ror gamma (ror¿)
UY36285A (es) Compuestos que inhiben la proteína mcl-1
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
AR103680A1 (es) Inhibidores selectivos de bace1
NI201800071A (es) Compuestos de isoindol
MX2017015740A (es) Moduladores de ror gamma (ror?).
MX2017015739A (es) Moduladores de ror gamma (ror?).
DOP2017000034A (es) Compuestos de imidazopiridazina
CO2019007186A2 (es) Moduladores de ror gamma (rorγ)
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705